英国耐甲氧西林金黄色葡萄球菌感染治疗指南更新
英国MRSA治疗指南在JAC-Antimicrobial Resistance更新,回顾了上一版发布十余年来新出现的抗菌药物证据及英国MRSA流行病学变化(尤其社区菌株),但文献中高质量证据匮乏,新版指南为不同等级证据与专家意见的混合,在无新证据处保留原有推荐,且未发现新药优于万古霉素的强证据。
要点
- 新版英国MRSA治疗指南基于十余年来新证据更新。
- 文献回顾发现高质量证据匮乏,指南为证据与专家意见混合。
- 未发现新药疗效优于万古霉素的强证据。
核心结论
- 新版英国MRSA治疗指南已更新发表,但支持推荐的高质量证据总体匮乏。
- 未能找到新药疗效优于万古霉素的强证据。
研究设计与样本
- 指南制定机构与方法:英国指南更新,发表于JAC-Antimicrobial Resistance,基于对上版发布十余年来新发表证据的回顾。
主要发现
- 更新涵盖自上一版指南以来获批用于革兰阳性菌感染(包括MRSA)的抗菌药物证据。
- 更新考虑英国MRSA流行病学变化对治疗的影响,尤其涉及循环社区菌株。
- 文献回顾的突出发现是高质量证据匮乏。
关键数值与推荐
- 在无新发表证据处保留部分原有推荐。
- 指南为不同等级证据与专家意见的混合。
临床怎么用
- 临床治疗MRSA感染应参照新版英国指南,并注意其推荐为证据与专家意见的混合。
- 选用新型抗菌药物时需考虑缺乏其优于万古霉素的强证据。
局限性
- 当前文献中高质量证据匮乏。
- 部分推荐因无新证据而沿用旧版。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The UK guidelines for the treatment of infections caused by MRSA have been updated and are published in JAC-Antimicrobial Resistance. The update reviews new evidence published since the previous UK guidelines were published over 10 years ago. It includes evidence relating to antimicrobial agents that have been licensed since then for the treatment of Gram-positive bacterial infections including MRSA. It also considers the impact on treatment of the changing epidemiology of MRSA in the UK, especially relating to circulating community strains. A striking finding from the current literature review was the paucity of good quality evidence. The current guidelines therefore represent a hybrid of varying degrees of evidence and expert opinion. Where there was no new published evidence, we have retained some of the existing recommendations. We were unable to find strong evidence of the superior efficacy of newer agents compared with that of vancomycin.
引用
- Brown NM, Brown EM. Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK. J Antimicrob Chemother. 2021. PMID: 33582806. doi:10.1093/jac/dkab036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。